X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2982) 2982
Publication (366) 366
Book Chapter (4) 4
Book Review (4) 4
Data Set (2) 2
Dissertation (2) 2
Magazine Article (2) 2
Conference Proceeding (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pyrimidinones - pharmacology (2062) 2062
humans (1829) 1829
animals (1397) 1397
index medicus (1174) 1174
male (910) 910
pharmacology & pharmacy (764) 764
female (636) 636
pyrimidinones - chemistry (622) 622
mice (557) 557
pyrimidinones - chemical synthesis (547) 547
rats (502) 502
chemistry, medicinal (491) 491
pyrimidinones - therapeutic use (470) 470
lopinavir (449) 449
structure-activity relationship (449) 449
adult (364) 364
biochemistry & molecular biology (347) 347
pyrimidinones - administration & dosage (335) 335
dose-response relationship, drug (314) 314
cell line, tumor (310) 310
pyrimidinones - pharmacokinetics (307) 307
hiv infections - drug therapy (288) 288
middle aged (264) 264
molecular structure (257) 257
antineoplastic agents - pharmacology (229) 229
cell line (212) 212
enzyme inhibitors - pharmacology (194) 194
chemistry, organic (193) 193
oncology (193) 193
in vitro techniques (184) 184
cancer (182) 182
article (181) 181
pyrimidinones - metabolism (181) 181
infectious diseases (180) 180
hiv-1 - drug effects (177) 177
thiazoles - pharmacology (172) 172
models, molecular (170) 170
analysis (168) 168
pyrimidinones - adverse effects (167) 167
mutation (163) 163
pyridones - pharmacology (162) 162
hiv (160) 160
ritonavir (159) 159
kinetics (156) 156
microbiology (152) 152
protein kinase inhibitors - pharmacology (151) 151
ritonavir - therapeutic use (149) 149
pharmacokinetics (147) 147
cells, cultured (146) 146
cell biology (145) 145
activation (144) 144
cell proliferation - drug effects (143) 143
drug therapy, combination (140) 140
pyridines - pharmacology (137) 137
pyrimidinones (137) 137
aged (136) 136
time factors (136) 136
hiv protease inhibitors - pharmacology (135) 135
antiviral agents (134) 134
apoptosis (134) 134
rats, sprague-dawley (134) 134
expression (131) 131
inhibitors (130) 130
protease inhibitors (128) 128
treatment outcome (128) 128
drug design (127) 127
research (127) 127
ritonavir - administration & dosage (127) 127
in-vitro (126) 126
resistance (124) 124
therapy (124) 124
pyrimidinones - blood (121) 121
derivatives (120) 120
administration, oral (118) 118
dogs (116) 116
hiv infections - virology (116) 116
immunology (116) 116
drug interactions (115) 115
disease models, animal (114) 114
hiv protease inhibitors - therapeutic use (114) 114
microbial sensitivity tests (110) 110
apoptosis - drug effects (107) 107
cells (106) 106
chemistry, multidisciplinary (106) 106
virology (106) 106
cell survival - drug effects (102) 102
ritonavir - pharmacology (100) 100
inhibition (98) 98
pyrimidines - pharmacology (97) 97
sulfonamides - pharmacology (97) 97
chemistry (96) 96
proteins (95) 95
signal transduction (95) 95
pharmacology (94) 94
protein binding (94) 94
anti-hiv agents - pharmacology (93) 93
ritonavir - pharmacokinetics (93) 93
phosphorylation (92) 92
drug synergism (91) 91
hiv protease inhibitors - administration & dosage (90) 90
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2878) 2878
Japanese (42) 42
German (23) 23
Chinese (11) 11
Spanish (11) 11
Russian (9) 9
French (6) 6
Italian (3) 3
Polish (3) 3
Hungarian (2) 2
Ukrainian (2) 2
Croatian (1) 1
Czech (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
Abstract Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | ORGAN TRANSPLANT RECIPIENTS | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | OF-THE-LITERATURE | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
Nature Communications, ISSN 2041-1723, 2014, Volume 5, Issue 1, p. 5712
Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway... 
BRAF INHIBITION | TYROSINE KINASE AXL | RAF INHIBITION | CELLS | BREAST-CANCER METASTASIS | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | IMPROVED SURVIVAL | MEK INHIBITORS | UP-REGULATION | CONFERS RESISTANCE | Prognosis | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Extracellular Signal-Regulated MAP Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | Melanoma - genetics | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Skin Neoplasms - pathology | Proto-Oncogene Proteins - antagonists & inhibitors | Microphthalmia-Associated Transcription Factor - metabolism | Signal Transduction | Proto-Oncogene Proteins - genetics | Imidazoles - pharmacology | Melanoma - pathology | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Skin Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Proto-Oncogene Proteins B-raf - genetics | Aminopyridines - pharmacology | Melanoma - drug therapy | Skin Neoplasms - genetics | Cell Line, Tumor | Oximes - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Microphthalmia-Associated Transcription Factor - genetics | Pyridones - pharmacology
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2015, Volume 125, Issue 3, pp. 1269 - 1285
Cholangiocarcinoma (CC) is typically diagnosed at an advanced stage and is refractory to surgical intervention and chemotherapy. Despite a global increase in... 
BREAST-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | INTRAHEPATIC CHOLANGIOCARCINOMA | THIOACETAMIDE | PORCUPINE | LIVER | BILIARY | BETA-CATENIN | RAT CHOLANGIOCARCINOMA | PROGRESSION | CANCER STEM-CELLS | Anisoles - pharmacology | Humans | Male | Cholangiocarcinoma - metabolism | Bile Ducts, Intrahepatic - metabolism | Keratins - metabolism | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Benzeneacetamides - pharmacology | Wnt Signaling Pathway | Bile Duct Neoplasms - drug therapy | Cell Survival - drug effects | Aniline Compounds - pharmacology | Bile Duct Neoplasms - metabolism | Pyrimidines - pharmacology | Rats, Sprague-Dawley | beta Catenin - metabolism | Heterocyclic Compounds, 2-Ring - pharmacology | Xenograft Model Antitumor Assays | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Macrophages - metabolism | Animals | Cholangiocarcinoma - drug therapy | Mice, Nude | Tamoxifen - pharmacology | Cell Line, Tumor | Macrophages - drug effects | Cell Proliferation - drug effects | Clodronic Acid - administration & dosage | Pyridines - pharmacology | Liposomes | Physiological aspects | Research | Tumor proteins | Wnt proteins | Oncology, Experimental | Cancer | Heparan sulfate | Medical research | Liver | Gene expression | Cancer therapies | Studies | Councils | Medical prognosis | Cell cycle | Ligands | Mutation | Tumors
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2007, Volume 82, Issue 2, pp. 197 - 203
Journal Article
PLOS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0125021
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance.... 
COLON-CANCER | MELANOMA | MEK INHIBITION | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | SYNTHETIC LETHAL INTERACTION | RESISTANCE | BRAF | KINASE INHIBITOR | BETA-CATENIN | EGFR | Triazoles - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Aza Compounds - pharmacology | Cell Line, Tumor - drug effects | Indazoles - administration & dosage | Quinolines - administration & dosage | Indoles - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Melanoma - genetics | Indoles - pharmacology | Pyrimidinones - pharmacology | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Aza Compounds - administration & dosage | Imidazoles - pharmacology | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | beta Catenin - metabolism | beta Catenin - genetics | Indazoles - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Triazoles - pharmacology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Oxazoles - administration & dosage | Oximes - pharmacology | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Oxazoles - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - pharmacology | Sulfonamides - administration & dosage | Drug therapy, Combination | Drug resistance | Drug therapy | Health aspects | Analysis | Melanoma
Journal Article
Cancer Cell, ISSN 1535-6108, 05/2014, Volume 25, Issue 5, pp. 697 - 710
MEK inhibitors are clinically active in BRAF melanomas but only marginally so in KRAS mutant tumors. Here, we found that MEK inhibitors suppress ERK signaling... 
LUNG-CANCER | CELLS | MELANOMA | ONCOLOGY | KINASE | C-RAF | IMPROVED SURVIVAL | BRAF | B-RAF | MUTATIONS | FEEDBACK INHIBITION | CELL BIOLOGY | Surface Plasmon Resonance | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Diphenylamine - pharmacology | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Melanoma - enzymology | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | MAP Kinase Kinase 1 - chemistry | MAP Kinase Kinase 1 - genetics | Diphenylamine - analogs & derivatives | RNA Interference | Melanoma - genetics | TNF Receptor-Associated Factor 3 - genetics | HEK293 Cells | Indoles - pharmacology | Pyrimidinones - pharmacology | Benzamides - pharmacology | Phosphorylation - drug effects | Cell Line | MAP Kinase Kinase 1 - antagonists & inhibitors | Proto-Oncogene Proteins - genetics | TNF Receptor-Associated Factor 3 - metabolism | Sulfonamides - pharmacology | Coumarins - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Pyridones - pharmacology | Analysis | Melanoma | Tumors | Index Medicus
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 2004, Volume 4, Issue 10, pp. 1079 - 1095
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in... 
CHEMISTRY, MEDICINAL | REVERSE-TRANSCRIPTASE INHIBITORS | ORALLY BIOAVAILABLE INHIBITOR | BIOLOGICAL EVALUATION | ANTIVIRAL ACTIVITY | SOCIETY-USA PANEL | ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | TYPE-1 PROTEASE | STRUCTURE-BASED DESIGN | Anti-HIV Agents - pharmacology | Pyridines - chemistry | Humans | Saquinavir - therapeutic use | Urethane - chemistry | Pyrimidinones - chemistry | Oligopeptides - therapeutic use | HIV Protease Inhibitors - pharmacology | Saquinavir - pharmacology | Urethane - therapeutic use | Atazanavir Sulfate | Phenylbutyrates - pharmacology | Ritonavir - therapeutic use | Oligopeptides - chemistry | Saquinavir - chemistry | Lopinavir | Pyrimidinones - therapeutic use | Models, Molecular | Sulfonamides - pharmacology | HIV Protease Inhibitors - therapeutic use | Nelfinavir - pharmacology | Anti-HIV Agents - chemistry | Carbamates | Urethane - pharmacology | Oligopeptides - pharmacology | Organophosphates - therapeutic use | Indinavir - pharmacology | Urethane - analogs & derivatives | HIV - drug effects | Molecular Mimicry | Phenylbutyrates - chemistry | Anti-HIV Agents - therapeutic use | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Molecular Structure | Pyridines - therapeutic use | Nelfinavir - therapeutic use | Peptides - chemistry | Sulfonamides - chemistry | Dipeptides - pharmacology | HIV Protease Inhibitors - chemistry | Clinical Trials as Topic | Dipeptides - chemistry | Ritonavir - chemistry | Peptides - pharmacology | Organophosphates - pharmacology | Sulfonamides - therapeutic use | HIV Infections - drug therapy | Organophosphates - chemistry | Pyridines - pharmacology | Peptides - therapeutic use | Indinavir - therapeutic use
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2013, Volume 19, Issue 5, pp. 1225 - 1231
Purpose: To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients with metastatic melanoma. Experimental Design: Thirty-five... 
RAF INHIBITION | MEK | THERAPY | ONCOLOGY | IMMUNOTHERAPY